Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714828 · ClinicalTrials.gov registry record · Phase 2
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03714828 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 11 participants.
The verdict
NCT03714828, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is single arm Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).
Interventions
- DRUG Injection of TVEC into target lesions - week 1-2
- DRUG Injection of TVEC into target lesions 3wks after 1st injection
- DRUG Injection of TVEC into target lesions 2wks after 2nd injection
- DRUG Injection of TVEC into target lesions 2wks after 3rd injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2023-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03714828
The ClinicalTrials.gov registry entry for NCT03714828 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Injection of TVEC into target lesions - week 1-2 is the first listed.
NCT03714828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03714828 about?
NCT03714828 is a clinical study titled "Study of TVEC in Patients With Cutaneous Squamous Cell Cancer". This is single arm Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).
What is the current status of trial NCT03714828?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-12-20. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT03714828?
The interventions under investigation include: Injection of TVEC into target lesions - week 1-2 (DRUG), Injection of TVEC into target lesions 3wks after 1st injection (DRUG), Injection of TVEC into target lesions 2wks after 2nd injection (DRUG), Injection of TVEC into target lesions 2wks after 3rd injection (DRUG).
Who is sponsoring clinical trial NCT03714828?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.